Clinical trial of VP 16–213 (NSC 141540) I.V. Twice weekly in advanced neoplastic disease a study by the cancer and leukemia group B
- 15 January 1980
Abstract
The epipodophyllotoxin derivative VP 16–213 (NSC 141540) was studied by the Cancer and Leukemia Group B in a broad phase II trial at three dose levels: 60 mg/m2, 90 mg/m2, and 135 mg/m2 I.V. twice weekly. No correlation between dose of VP 16–213 and response frequency in a particular disease category could be demonstrated. Of the 382 patients, 8% obtained a complete (CR) or partial remission (PR), 8% showed improvement, and 14% had stable disease. By tumor type the best responses were obtained in lymphomas (8/31 CR + PR), uterus (2/9), prostate (1/5), rhabdomyosarcoma (2/6), neuroblastoma (2/4), colon/rectum (5/81), other gastrointestinal (4/32). In lung tumors, 4/80 patients obtained CR or PR. VP 16–213 has definite antineoplastic activity but the response frequency with the twice weekly schedule may be lower than that reported with other schedules.This publication has 4 references indexed in Scilit:
- VP-16-213 MONOTHERAPY FOR REMISSION INDUCTION OF SMALL CELL LUNG-CANCER - RANDOMIZED TRIAL USING 3 DOSAGE SCHEDULES1978
- VM 26 and VP 16–213: A comparative analysisCancer, 1977
- Epipodophyllotoxin VP 16213 in Treatment of Acute Leukaemia--Haematosarcoma and Solid TumoursBMJ, 1973
- Activity of a new glycosidic lignan derivative (VP 16-213) related to podophyllotoxin in experimental tumorsEuropean Journal of Cancer (1965), 1973